• 1
  • 2
    Boullata JI. Drug disposition in obesity and protein-energy malnutrition. Proc Nutr Soc. 2010; 69:543550.
  • 3
    Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet. 1989; 17(Suppl 1):6888.
  • 4
    Raiten DJ. Nutrition and pharmacology: general principles and implications for HIV. Am J Clin Nutr. 2011; 94:1697S1702S.
  • 5
    Uganda Bureau of Statistics, Kampala Uganda. Uganda Demographic and Health Survey., Accessed May 2013. 2013. Ref Type: Electronic Citation.
  • 6
    Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS ONE. 2010; 5:e10340.
  • 7
    Young S, Wheeler A, McCoy A, Weiser S. A review of the role of food insecurity in adherence to care and treatment among adult and pediatric populations living with HIV and AIDS. AIDS Behav 2013 Jul 11. [Epub ahead of print].
  • 8
    Savic RM, Barrail-Tran A, Duval X, et al. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther. 2012; 92:575583.
  • 9
    Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Methods Med Res. 1999; 8:247262.
  • 10
    Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol. 2005; 45:461467.
  • 11
    Gonzalez de RD, Blanco F, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS. 2003; 17:443445.
  • 12
    Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr. 2003; 33:594600.
  • 13
    Wateba MI, Billaud E, Dailly E, Jolliet P, Raffi F. Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients. HIV Med. 2006; 7:197199.
  • 14
    Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J. 2005; 24:874879.
  • 15
    Leth FV, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses. 2006; 22:232239.
  • 16
    Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit. 2004; 26:267270.
  • 17
    Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003; 47:350359.
  • 18
    Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials 2000; 1:1319.
  • 19
    Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:7175.
  • 20
    Ciccarelli N, Fabbiani M, Di GS, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76:14031409.
  • 21
    Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 41:16481653.
  • 22
    Abrams B, Duncan D, Hertz-Picciotto I. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. J Acquir Immune Defic Syndr. 1993; 6:949958.
  • 23
    Baum MK, Shor-Posner G. Nutritional status and survival in HIV-1 disease. AIDS 1997; 11:689690.
  • 24
    Koethe JR, Lukusa A, Giganti MJ, et al. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010; 53:507513.
  • 25
    Weiser SD, Fernandes KA, Brandson EK, et al. The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr. 2009; 52:342349.
  • 26
    Weiser SD, Tsai AC, Gupta R, et al. Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. AIDS 2012; 26:6775.
  • 27
    Mehta S, Manji KP, Young AM, et al. Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women. Am J Clin Nutr. 2008; 87:16391649.
  • 28
    Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010; 54:381388.
  • 29
    Calcagno A, D'Avolio A, Simiele M, et al. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol. 2012; 74:134140.
  • 30
    Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011; 52:12671275.
  • 31
    van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011; 56:333339.
  • 32
    Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009; 23:471478.
  • 33
    Young S, Murray K, Mwesigwa J, et al. Maternal nutritional status predicts adverse birth outcomes among HIV-infected Rural Ugandan women receiving combination antiretroviral therapy. PLoS ONE. 2012; 7:e41934.
  • 34
    Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, Fletcher CV. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother. 2004; 48:979984.
  • 35
    Kromdijk W, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J Antimicrob Chemother. 2012; 67:12111216.
  • 36
    Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008; 22:34013409.
  • 37
    Coates J, Swindale A, Bilinsky P. Household food insecurity access scale (HFIAS) for measurement of food access: indicator guide Washington, DC: Food and Nutrition Technical Assistance Project. 2007; 131.
  • 38
    Deitchler M, Ballard T, Swindale A, Coates J. Introducing a simple mesure of household hunger for cross-cultural use. Tech Note FANTA. 2011; 2:113.
  • 39
    Mukonzo JK, Roshammar D, Waako P, et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009; 68:690699.
  • 40
    Bouillon-Pichault M, Jullien V, Azria E, et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother. 2009; 63:12231232.
  • 41
    Bano G, Raina RK, Sharma DB. Pharmacokinetics of carbamazepine in protein energy malnutrition. Pharmacology. 1986; 32:232236.
  • 42
    Krishnaswamy K, Ushasri V, Naidu NA. The effect of malnutrition on the pharmacokinetics of phenylbutazone. Clin Pharmacokinet. 1981; 6:152159.
  • 43
    Levine RR. Factors affecting gastrointestinal absorption of drugs. Am J Dig Dis. 1970; 15:171188.
  • 44
    Winter TA. The effects of undernutrition and refeeding on metabolism and digestive function. Curr Opin Clin Nutr Metab Care 2006; 9:596602.
  • 45
    Winter TA, Lemmer ER, O'Keefe SJ, Ogden JM. The effect of severe undernutrition, and subsequent refeeding on digestive function in human patients. Eur J Gastroenterol Hepatol. 2000; 12:191196.
  • 46
    Ferraris RP, Carey HV. Intestinal transport during fasting and malnutrition. Annu Rev Nutr. 2000; 20:195219.
  • 47
    Weiser SD, Young SL, Cohen CR, et al. Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr. 2011; 94:1729S1739S.
  • 48
    Lamorde M, Byakika-Kibwika P, Tamale WS, et al. Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in Ugandan adults. AIDS Res Treat. 2012; 2012:105980.
  • 49
    Lamorde M, Byakika-Kibwika P, Boffito M, et al. Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults. J Acquir Immune Defic Syndr. 2012; 60:295298.
  • 50
    Ibarra M, Fagiolino P, Vazquez M, et al. Impact of food administration on lopinavir-ritonavir bioequivalence studies. Eur J Pharm Sci. 2012; 46:516521.
  • 51
    Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007; 44:401410.
  • 52
    Kaul S, Ji P, Lu M, Nguyen KL, Shangguan T, Grasela D. Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. Am J Health Syst Pharm. 2010; 67:217222.
  • 53
    Gracey M, Cullity GJ, Suharjono,   Sunoto.   The stomach in malnutrition. Arch Dis Child. 1977; 52:325327.
  • 54
    Griffin L, Annaert P, Brouwer KL. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci. 2011; 100:36363654.
  • 55
    Aweeka FT, Stek A, Best BM, et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010; 11:232238.
  • 56
    Ashton JM, Bolme P, Zerihun G. Protein binding of salicylic and salicyluric acid in serum from malnourished children: the influence of albumin, competitive binding and non-esterified fatty acids. J Pharm Pharmacol. 1989; 41:474480.
  • 57
    Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008; 13:675685.
  • 58
    King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS. 2008; 22:17091717.
  • 59
    Gorowara M, Burger D, Hill A, Ruxrungtham K. Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries. Curr Opin HIV AIDS. 2010; 5:9096.
  • 60
    Molto J, Barbanoj MJ, Miranda C, et al. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin Pharmacokinet. 2008; 47:681692.
  • 61
    Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006; 20:19311939.
  • 62
    Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008; 49:485491.
  • 63
    Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012; 59:245252.
  • 64
    Lee JH, Suh OK, Lee MG. Pharmacokinetic changes in drugs during protein-calorie malnutrition: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Arch Pharm Res. 2004; 27:693712.
  • 65
    Mehta S, Nain CK, Sharma B, Mathur VS. Disposition of four drugs in malnourished children. Drug Nutr Interact. 1982; 1:205211.
  • 66
    Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:11811183.
  • 67
    Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003; 139:810816.
  • 68
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:2130.
  • 69
    Garcia de Olalla OP, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002; 30:105110.
  • 70
    Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001; 33:14171423.
  • 71
    Gandhi M, Greenblatt RM, Bacchetti P, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012; 206:14531461.
  • 72
    Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010; 24:21932200.
  • 73
    Ramautarsing RA, van der LJ, Gorowara M, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS 2011; 25:12991303.
  • 74
    BMI classification WHO., accessed May 2013; 2013.